Amgen (AMGN) and UCB announced that the U.S. Food and Drug Administration (FDA) has granted approval of Evenity™(romosozumab-aqqg) for osteoporosis in postmenopausal women at high risk for bone fracture. Evenity is different from all other osteoporosis products as it is a bone builder that increases bone formation and, to a lesser extent, reduces bone loss and, consequently, reduces the risk of fracture.
A full course of Evenity therapy is: 12 monthly doses administered . . .